FOX04-DRI (10mg Vial) Dosage Protocol
Table of Contents
Quickstart Highlights
FOXO4-DRI (also known as Proxofim) is a synthetic D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4–p53 protein interaction[1][2]. When this interaction is blocked, p53 translocates to the mitochondria in senescent cells, triggering their programmed death while sparing healthy cells[1]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for precise insulin-syringe measurements.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 250–500 mcg once daily (gradual titration over 16 weeks).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution,refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles[8].
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously[7]. This schedule uses the standard 3.0 mL dilution to maintain injection volumes under 0.2 mL for all doses. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake)[8].
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once-daily regimen.
- Goal : Selectively clear senescent cells via disruption of FOXO4–p53 binding[1][2].
- Schedule : Daily subcutaneous injections for 8–16 weeks with gradual dose escalation.
- Dose Range : 250–500 mcg daily; starting low and titrating upward over time.
- Reconstitution : 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage : Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw[8].
Dosing Protocol
Suggested daily titration approach.
- Start : 250 mcg daily for the first 4 weeks; increase gradually as tolerated.
- Mid-Phase: 375 mcg daily during Weeks 5–8.
- Target: 500 mcg daily by Weeks 9–16.
- Frequency: Once per day (subcutaneous)[7].
- Cycle Length: 8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated[4].
- Timing: Any consistent time; rotate injection sites to minimize local irritation.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure[8].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 month when using bacteriostatic water[8].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- If long-term storage of reconstituted solution is needed, aliquot into single-use vials and freeze to minimize degradation[8].
Suppilies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (FOXO4-DRI, 10 mg each): :
-
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
- Insulin Syringes (U-100): </b
-
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.:
-
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
-
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes (typically 29–31 gauge, 0.5 inch needle) for each injection[9]; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) at least 1 inch apart to reduce local irritation[10].
- Clean the injection site with an alcohol swab and allow to dry before injecting[9].
- Inject slowly and steadily; no need to aspirate for subcutaneous injections[11].
- Document daily dose and site rotation to maintain consistency throughout the protocol.
How This Works
FOXO4-DRI is a synthetic peptide that selectively targets senescent cells by blocking the FOXO4–p53 protein interaction[1][2]. In normal cells, FOXO4 binds to p53 and sequesters it in the nucleus. In senescent cells, disrupting this interaction causes p53 to translocate to the mitochondria, triggering apoptotic cell death specifically in aged, dysfunctional cells while sparing healthy ones[1]. Animal studies have demonstrated that FOXO4-DRI can reduce senescent cell burden, improve tissue function, and mitigate age-related pathologies[3][4][5]. The peptide’s D-retro-inverso configuration enhances its stability and resistance to proteolytic degradation[2].
Potential Benefits & Side Effects
Observations from preclinical literature.
- Promotes selective clearance of senescent cells in various tissues, including aged organs and pathological conditions[3][4][5].
- Animal studies show improvements in tissue regeneration, reduced inflammation, and enhanced organ function following senescent cell clearance[3][5].
- In aged mice, FOXO4-DRI treatment improved testosterone levels and markers of cellular health[3].
- No human clinical safety or efficacy data currently exist[6]; tolerability in humans remains uncharacterized.
- Injection-site reactions (mild redness, irritation) may occur with subcutaneous administration[10].
Lifestyle Factors
Complementary strategies for optimal outcomes.
- Maintain a balanced, nutrient-dense diet rich in antioxidants and anti-inflammatory compounds.
- Combine regular resistance training and cardiovascular activity to support cellular health and metabolic function.
- Prioritize sleep quality and stress management, both of which influence cellular senescence pathways.
- Stay well-hydrated and avoid excessive alcohol consumption or smoking, which can accelerate cellular aging.
Injection Technique
- Clean the vial stopper and skin with alcohol; allow to dry[9].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 90° for adequate fat layer, 45° if thin)[11][12].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation[10].
- Release the pinch and withdraw the needle; apply gentle pressure with gauze if slight bleeding occurs.
Recommended Source
We recommend Go Alpha Labs for high-purity FOXO4-DRI (10 mg).
Why Go Alpha Labs?
- Verifies ≥99% purity through independent lab testing
- Trusted by researchers seeking reliable results
- Follows rigorous manufacturing standards for consistent quality
Important Note:
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References:
| Source | Link |
|---|---|
| Nature Communications Biology – FOXO4-DRI induces keloid senescent fibroblast apoptosis | View Source |
| Nature Cell – Original FOXO4-DRI senescent-cell apoptosis discovery | View Source |
| Aging (Albany NY) – FOXO4-DRI restores testosterone secretion in aged mice | View Source |
| Journal of Cellular and Molecular Medicine – FOXO4 peptide reduces bleomycin-induced pulmonary fibrosis | View Source |
| Cell – Senolytic mechanism context: clearance of senescent cells rejuvenates stem cells | View Source |
| Aging (Albany NY) — Methods & Protocols – FOXO4-DRI safety note (no human clinical dosing) | View Source |
| PubMed – Peptide metabolism assay for subcutaneous injections | View Source |
| Bachem – Care & handling of peptides (storage, reconstitution, stability) | View Source |
| MedlinePlus – Subcutaneous injection technique & safety | View Source |
| American Diabetes Association – Injection site rotation guidance | View Source |
| CDC – SQ injection angle & site (no aspiration) | View Source |
| CDC (SQ Injection PDF) – Diagram & administration guidance | View Source |
| NCBI Bookshelf – Best practices for injection preparation & asepsis | View Source |
| PMC – Subcutaneous drug injection review | View Source |
| go alpha labs – FOXO4-DRI product page (quality documentation) | View Source |